CN108450000A - 痰液样本中无细胞的核小体作为生物标记的用途 - Google Patents

痰液样本中无细胞的核小体作为生物标记的用途 Download PDF

Info

Publication number
CN108450000A
CN108450000A CN201680050736.7A CN201680050736A CN108450000A CN 108450000 A CN108450000 A CN 108450000A CN 201680050736 A CN201680050736 A CN 201680050736A CN 108450000 A CN108450000 A CN 108450000A
Authority
CN
China
Prior art keywords
cell
nucleosomes
epigenetic
subject
sputum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680050736.7A
Other languages
English (en)
Chinese (zh)
Inventor
J.米卡莱夫
M.赫佐格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belgian Volition SPRL
Original Assignee
Belgian Volition SPRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belgian Volition SPRL filed Critical Belgian Volition SPRL
Publication of CN108450000A publication Critical patent/CN108450000A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680050736.7A 2015-07-01 2016-07-01 痰液样本中无细胞的核小体作为生物标记的用途 Pending CN108450000A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1511512.4A GB201511512D0 (en) 2015-07-01 2015-07-01 Use of cell-free nucleosomes as biomarkers
GB1511512.4 2015-07-01
PCT/GB2016/051994 WO2017001863A1 (en) 2015-07-01 2016-07-01 Use of cell-free nucleosomes as biomarkers in sputum samples

Publications (1)

Publication Number Publication Date
CN108450000A true CN108450000A (zh) 2018-08-24

Family

ID=53872486

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680050736.7A Pending CN108450000A (zh) 2015-07-01 2016-07-01 痰液样本中无细胞的核小体作为生物标记的用途

Country Status (7)

Country Link
US (1) US20180306804A1 (enExample)
EP (1) EP3317671B1 (enExample)
JP (1) JP7094700B2 (enExample)
CN (1) CN108450000A (enExample)
ES (1) ES2772701T3 (enExample)
GB (1) GB201511512D0 (enExample)
WO (1) WO2017001863A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3759249T3 (da) * 2018-03-01 2023-10-30 Epicypher Inc Kvantificering af nukleosommodifikationer ved anvendelse af kemisk definerede rekombinante nukleosomer
US11154240B2 (en) 2019-04-02 2021-10-26 Kpn Innovations Llc Methods and systems for utilizing diagnostics for informed vibrant constitutional guidance
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
ES2988371T3 (es) * 2019-12-02 2024-11-20 Belgian Volition Srl Uso de nucleosomas libres de células como biomarcadores
US11289206B2 (en) 2020-06-02 2022-03-29 Kpn Innovations, Llc. Artificial intelligence methods and systems for constitutional analysis using objective functions
US12176108B2 (en) 2020-06-02 2024-12-24 Kpn Innovations Llc Artificial intelligence methods and systems for constitutional analysis using objective functions
US11211158B1 (en) 2020-08-31 2021-12-28 Kpn Innovations, Llc. System and method for representing an arranged list of provider aliment possibilities
GB202310137D0 (en) * 2023-07-03 2023-08-16 Belgian Volition Srl Method for the detection of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229772B1 (en) * 1998-03-18 2007-06-12 Roche Diagnostics Gmbh Detection of apoptotic products
CN104053993A (zh) * 2011-09-01 2014-09-17 新加坡意志私人有限公司 用于检测含组蛋白变体的核小体的方法
CN104067125A (zh) * 2011-12-07 2014-09-24 新加坡意志私人有限公司 用于检测核小体加合物的方法
CN104067124A (zh) * 2011-09-01 2014-09-24 新加坡意志私人有限公司 用于检测含核苷酸的核小体的方法
WO2015048535A1 (en) * 2013-09-27 2015-04-02 Natera, Inc. Prenatal diagnostic resting standards

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201012662D0 (en) 2010-07-28 2010-09-15 Valirx Plc Method for detecting the presence of a gynaecological growth
GB201303575D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229772B1 (en) * 1998-03-18 2007-06-12 Roche Diagnostics Gmbh Detection of apoptotic products
CN104053993A (zh) * 2011-09-01 2014-09-17 新加坡意志私人有限公司 用于检测含组蛋白变体的核小体的方法
CN104067124A (zh) * 2011-09-01 2014-09-24 新加坡意志私人有限公司 用于检测含核苷酸的核小体的方法
CN104067125A (zh) * 2011-12-07 2014-09-24 新加坡意志私人有限公司 用于检测核小体加合物的方法
WO2015048535A1 (en) * 2013-09-27 2015-04-02 Natera, Inc. Prenatal diagnostic resting standards

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BELINSKY, SA 等。: "Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.", 《CANCER RESEARCH》 *
M.A.VAN DER DRIFT 等。: "Can free DNA be detected in sputum of lung cancer patients?", 《LUNG CANCER》 *
TUFMAN, AMANDA 等。: "Biological markers in lung cancer: A clinician"s perspective", 《CANCER BIOMARKERS》 *

Also Published As

Publication number Publication date
WO2017001863A1 (en) 2017-01-05
JP2018529931A (ja) 2018-10-11
ES2772701T3 (es) 2020-07-08
EP3317671B1 (en) 2019-11-13
HK1255151A1 (en) 2019-08-09
EP3317671A1 (en) 2018-05-09
GB201511512D0 (en) 2015-08-12
US20180306804A1 (en) 2018-10-25
JP7094700B2 (ja) 2022-07-04

Similar Documents

Publication Publication Date Title
JP6263474B2 (ja) ヌクレオソームアダクト検出法
JP6494703B2 (ja) ヒストン変種含有ヌクレオソーム検出法
JP6322845B2 (ja) ヌクレオチド含有ヌクレオソーム検出法
EP3317671B1 (en) Use of cell-free nucleosomes as biomarkers in sputum samples
KR102369544B1 (ko) 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도
EP3317672B1 (en) Use of cell-free nucleosomes as biomarkers in fecal samples
HK1255151B (en) Use of cell-free nucleosomes as biomarkers in sputum samples
HK40083883A (en) Method for detecting nucleosome adducts
HK1255090A1 (en) Use of cell-free nucleosomes as biomarkers in fecal samples
HK1255090B (en) Use of cell-free nucleosomes as biomarkers in fecal samples

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180824

RJ01 Rejection of invention patent application after publication